Impact intelligence for biopharma
Our product is impact.
Almost every engagement strategy in biopharma is built on a list — people ranked by title, publication count and prescribing volume. Those are stand-ins for influence. They are not influence.
Sipher6 maps the actual structure of your disease community, using the same network analytics that intelligence agencies use to understand global threat networks. Then we tell you who moves your community — in full detail.
Illustrative impact map — a community of 149 individuals, 369 collaborative links and 12 identified activity clusters. The pulse traces how one engagement with a key person influences others.
From a scoping call to a live, disease-specific platform built to your specification, within hours. Not weeks.
Every person, trial and institution in your global disease area — not a filtered list.
Your map, your targets, your deliverables. Proprietary to you and never shared with another client.
Our highly efficient technology means exceptional affordability for corporate budgets.
The problem with lists
Influence isn’t a ranking.
It’s a structure.
The most powerful influence on human behavior is other humans. A ranked list can’t see that, because it measures each person in isolation. A map measures the space between them. Same twelve individuals, from all sides.
What a list sees
Ranked by outputTwelve individuals in a disease community, ordered by an activity count — the way most target lists are built.
- 01A-01148
- 02A-02131
- 03A-03122
- 04A-04118
- 05A-05109
- 06A-0697
- 07A-0791
- 08A-0886
- 09A-0974
- 10A-1071
- 11A-1168
- 12A-1262
A-01 tops the list. A-09 is a second-page name that most field plans never reach.
What the map sees
The same twelveThree research clusters that barely connect. Circle size is activity count — so the biggest circle is still A-01.
A-01 influences four of the other eleven. Three of them in A-01’s own cluster.
A-09 influences ten of the other eleven, across all three clusters.
A-09 ranks ninth by activity volume but first by reach of influence.
Half the activity of the top name, but two and a half times the reach — the only person who connects with all three clusters that otherwise don’t talk. Engage A-01 and one cluster hears you loudly. Engage A-09 and more of the community hears you.
Individuals reached within two steps.
All examples are from a synthetic community, not actual client data.
The method
Four steps, and the fourth one really matters.
Most platforms stop at step three and hand you a dashboard. We finish the job.
Gather the full record
Focus on the forest, not the trees. We collect the complete data footprint of your entire global disease community.
Clean & disambiguate
We build in accuracy. We resolve every name, affiliation and identifier so the outputs reflect reality, without noise or duplication.
Model the network
We apply true social network analytics — the discipline that intelligence agencies use for counterterrorism — to map how information and influence actually move your community.
You get the levers
It’s not just another dashboard to interpret. You get named people, named institutions, the reason each one is a lever, and the path to reach them.
Capabilities
Engage your targets with precision.
We enable medical affairs and commercial strategists to know exactly who to engage — and why — to reach their specific objectives.
Field optimization
Optimize your resources and call lists around relationships that deliver maximum impact on sentiment, opinions and behavior.
Insight collection plans
A complete, evidence-based map of your disease community, so your insight-gathering leaves no blind spots and no gaps.
Rising Stars
Build key relationships before everyone else recognizes they’re key, using validated network momentum measures to identify tomorrow’s leaders.
Competitive engagement data
See competitor targets at the community, institution or IDN level, so you can understand — and outmaneuver — the competition.
Advisory board design
Advisory strategies that ensure you hear the right voices — on every relevant topic — including the ones you didn’t know about.
Global & institutional mapping
See the key nodes of influence in the geographies that matter to your strategy, and who’s key to impacting any organization or IDN (from inside or out).
Trial site & investigator strategy
Data that guides optimal site placement and investigator recruitment for faster, more reliable enrollment.
Need just one of the above? Quickly? We can do that.
How you buy it
A platform, not a project.
License a disease-specific Sipher6 platform built to your specification. No statement of work, no six-week discovery, no per-seat math.
Built in hours
Scoped to your disease area and objectives, then stood up the same day.
Annual license, unlimited users
Everyone who needs the map gets the map. No seat counting, no access tiers.
Rescope on the fly
Unlimited rescoping and continuous data refreshes as your strategy moves.
Proprietary to you
Your data and deliverables are yours. Never pooled, never shared with another client.
Lineage
Where the method comes from.
This isn’t a new idea with a new name on it. It’s a hundred years of network science and seventy years of intelligence tradecraft, pointed at a disease community.
1929
Karinthy’s “Chains” poses six degrees of separation as a game.
1948
British intelligence in Malaya builds the first rigorous method for mapping an insurgent network.
1967
Milgram’s small-world experiment tests it empirically. Successful chains average about six intermediaries.
1972
Crane’s Invisible Colleges shows informal collaboration is how ideas spread in science.
1990s
Scale-free models and statistical mechanics turn networks into dynamic systems. Modern network analytics is born.
2010
Voxx Analytics brings military network methodology to scientific influence in life sciences.
Today
Sipher6, founded by Voxx’s founder, applies it to mapping impact in your disease community.
Leadership
Tony Page
Tony has spent three decades applying government intelligence methodologies to pharmaceutical business problems. After serving as a strategic intelligence officer, he founded and operated companies in competitive intelligence, promotional material analytics, social listening and KOL identification. His companies were acquired by Within3 in 2021, where he served as SVP of Insight Analytics for five years before founding Sipher6 as the first impact analytics platform.
Tell us your disease area. We’ll show you the dials.
Bring an objective and a therapeutic area. We’ll come back with the specific people, institutions and conversations that determine whether you hit it.
- 01We have a quick scoping conversation about your objectives.
- 02We walk you through your community.
- 03You take possession, if it earns its place.